daxibotulinumtoxinA

DaxibotulinumtoxinA (DAXXIFY) is a long-acting botulinum toxin type A neuromodulator developed by Revance Therapeutics. It is the first botulinum toxin formulated with a proprietary 35-amino acid stabilizing peptide (RTP004) and without human serum albumin or animal-derived components. The drug's mechanism of action involves the proteolytic cleavage of SNAP-25, a protein essential for the docking and fusion of acetylcholine-containing vesicles with the presynaptic membrane at the neuromuscular junction. This inhibition of acetylcholine release results in temporary muscle relaxation. While FDA-approved for the treatment of glabellar lines and cervical dystonia, it is currently being investigated by Ki Health Partners LLC for the preventive treatment of high-frequency and chronic migraine using a novel subcutaneous injection paradigm (the "EEG paradigm") at a 310U dose.

Brand names

DAXXIFY

Other names

daxibotulinumtoxinA-lanm